Research programme: interleukin-3 monoclonal antibody - Baxalta

Drug Profile

Research programme: interleukin-3 monoclonal antibody - Baxalta

Alternative Names: SM 401

Latest Information Update: 06 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SuppreMol; University of Regensburg
  • Developer Baxalta
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 04 Mar 2015 SuppreMol has been acquired by Baxter International
  • 07 Mar 2014 No development reported - Preclinical for Rheumatoid arthritis in Germany (parenteral)
  • 24 Jul 2012 Preclinical trials in Rheumatoid arthritis in Germany (parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top